The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | CLL updates from SOHO 2022: novel treatment strategies, the promise of next-generation BTK inhibitors & more
In this discussion, Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Catherine Coombs, MD, University of North Carolina, Chapel Hill, NC, discuss key updates in chronic lymphocytic leukemia (CLL) from the SOHO 2022 Annual Meeting. The experts comment on novel treatment strategies, the role of chemotherapy in the era of novel agents, the promise of next-generation BTK inhibitors, and more.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
